First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton

Core Insights - Lifeward Ltd. has made significant progress in securing Medicare reimbursement for its ReWalk 7 Personal Exoskeleton, marking a milestone in expanding access for individuals with spinal cord injuries [1][2] - The company has successfully received its first payment from a commercial Medicare Advantage Plan, indicating a growing acceptance of its innovative medical technology [1][2] - The Centers for Medicare & Medicaid Services (CMS) has established a reimbursement pathway for personal exoskeletons, which has streamlined the claims process, allowing for quicker approvals and payments [2] Company Overview - Lifeward is a leader in medical technology focused on transforming the lives of individuals with physical limitations or disabilities, with a mission to drive innovation in rehabilitation and recovery [3] - The company's product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, showcasing its commitment to delivering groundbreaking solutions [3] - Founded in 2001, Lifeward operates in the United States, Israel, and Germany, emphasizing its global reach and impact in the healthcare sector [3]